FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2029587445> ?p ?o ?g. }

• W2029587445 endingPage "66" @default.
• W2029587445 startingPage "60" @default.
• W2029587445 abstract "Intrapatient variability in drug plasma concentrations is critical to the use of therapeutic drug monitoring with efavirenz, a non-nucleoside reverse-transcriptase inhibitor. Marked intrapatient variability, particularly for concentrations near the minimal therapeutic concentration, could be a predictor of virologic failure, meaning that a single concentration is of limited value. Previous reports on efavirenz intra-individual variability were obtained only in follow-up periods of 3 to 12 months and do not provide a rationale for the periodicity of sample measurements needed in long-term therapy to identify patients with a large variability and increased risk of therapeutic failure. The aim of this work was to investigate intra-individual variability in efavirenz plasma concentrations over a long-term follow-up period to support therapeutic drug monitoring. In a case series study, clinical and laboratory data were collected from all HIV-positive adults at the immunodeficiency outpatient clinic who were on regimens containing efavirenz in 2002 and who gave their informed consent (n = 31). Efavirenz plasma concentrations were measured throughout a 3 year period, without dose adjustments. For each patient, 6 to 12 samples were obtained over the follow-up period with an interval of at least 3 months between each sample. Mean plasma concentrations (mg/L) in the first, second, and third year of follow-up were 2.20 +/- 0.64, 2.17 +/- 0.68, and 2.31 +/- 0.57. Mean intra-individual variability throughout the first, second, and third year of study was 27%, 31%, and 25%, ranging from 12% to 63%. No differences in intrapatient variability in efavirenz plasma concentrations were found between females and males, HBV/HCV and HBV/HCV patients, or age above/below 40 years. Mean values (intra-individual variability) in plasma concentrations (mg/L) found in 3 of 31 patients who experienced virologic failure were 1.78 (42%), 1.52 (16%), and 1.68 (45%). The high interindividual variability and low maintained values of intrapatient variability in plasma concentrations support therapeutic drug monitoring, which could be based on measurements taken quarterly during the first year of therapeutics. In patients presenting high values of intra-individual variability (eg, >40%) associated with low plasma concentrations (eg, <2 mg/L), more frequent measurements over longer periods (more than 1 yr) of controlled concentrations might be recommended, but this requires further investigation." @default.
• W2029587445 created "2016-06-24" @default.
• W2029587445 creator A5015034643 @default.
• W2029587445 creator A5026013020 @default.
• W2029587445 creator A5041006420 @default.
• W2029587445 creator A5058622754 @default.
• W2029587445 creator A5070983547 @default.
• W2029587445 creator A5073789918 @default.
• W2029587445 creator A5076501395 @default.
• W2029587445 date "2008-02-01" @default.
• W2029587445 modified "2023-10-18" @default.
• W2029587445 title "Intra-Individual Variability in Efavirenz Plasma Concentrations Supports Therapeutic Drug Monitoring Based on Quarterly Sampling in the First Year of Therapy" @default.
• W2029587445 cites W139116624 @default.
• W2029587445 cites W1501551071 @default.
• W2029587445 cites W1966426432 @default.
• W2029587445 cites W1966436517 @default.
• W2029587445 cites W1981458531 @default.
• W2029587445 cites W1990562500 @default.
• W2029587445 cites W1998765853 @default.
• W2029587445 cites W2011912864 @default.
• W2029587445 cites W2030747457 @default.
• W2029587445 cites W2040114578 @default.
• W2029587445 cites W2042972694 @default.
• W2029587445 cites W2064068523 @default.
• W2029587445 cites W2073232204 @default.
• W2029587445 cites W2083192082 @default.
• W2029587445 cites W2106737113 @default.
• W2029587445 cites W2160125596 @default.
• W2029587445 cites W2316209820 @default.
• W2029587445 cites W2321248858 @default.
• W2029587445 cites W3191280760 @default.
• W2029587445 doi "https://doi.org/10.1097/ftd.0b013e318160ce76" @default.
• W2029587445 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18223464" @default.
• W2029587445 hasPublicationYear "2008" @default.
• W2029587445 type Work @default.
• W2029587445 sameAs 2029587445 @default.
• W2029587445 citedByCount "22" @default.
• W2029587445 countsByYear W20295874452012 @default.
• W2029587445 countsByYear W20295874452014 @default.
• W2029587445 countsByYear W20295874452016 @default.
• W2029587445 countsByYear W20295874452017 @default.
• W2029587445 countsByYear W20295874452019 @default.
• W2029587445 countsByYear W20295874452020 @default.
• W2029587445 countsByYear W20295874452021 @default.
• W2029587445 crossrefType "journal-article" @default.
• W2029587445 hasAuthorship W2029587445A5015034643 @default.
• W2029587445 hasAuthorship W2029587445A5026013020 @default.
• W2029587445 hasAuthorship W2029587445A5041006420 @default.
• W2029587445 hasAuthorship W2029587445A5058622754 @default.
• W2029587445 hasAuthorship W2029587445A5070983547 @default.
• W2029587445 hasAuthorship W2029587445A5073789918 @default.
• W2029587445 hasAuthorship W2029587445A5076501395 @default.
• W2029587445 hasConcept C112705442 @default.
• W2029587445 hasConcept C126322002 @default.
• W2029587445 hasConcept C142462285 @default.
• W2029587445 hasConcept C159047783 @default.
• W2029587445 hasConcept C19831878 @default.
• W2029587445 hasConcept C2776452011 @default.
• W2029587445 hasConcept C2777351918 @default.
• W2029587445 hasConcept C2780035454 @default.
• W2029587445 hasConcept C2780272996 @default.
• W2029587445 hasConcept C2780727368 @default.
• W2029587445 hasConcept C2781432083 @default.
• W2029587445 hasConcept C2993143319 @default.
• W2029587445 hasConcept C3013748606 @default.
• W2029587445 hasConcept C71924100 @default.
• W2029587445 hasConcept C98274493 @default.
• W2029587445 hasConceptScore W2029587445C112705442 @default.
• W2029587445 hasConceptScore W2029587445C126322002 @default.
• W2029587445 hasConceptScore W2029587445C142462285 @default.
• W2029587445 hasConceptScore W2029587445C159047783 @default.
• W2029587445 hasConceptScore W2029587445C19831878 @default.
• W2029587445 hasConceptScore W2029587445C2776452011 @default.
• W2029587445 hasConceptScore W2029587445C2777351918 @default.
• W2029587445 hasConceptScore W2029587445C2780035454 @default.
• W2029587445 hasConceptScore W2029587445C2780272996 @default.
• W2029587445 hasConceptScore W2029587445C2780727368 @default.
• W2029587445 hasConceptScore W2029587445C2781432083 @default.
• W2029587445 hasConceptScore W2029587445C2993143319 @default.
• W2029587445 hasConceptScore W2029587445C3013748606 @default.
• W2029587445 hasConceptScore W2029587445C71924100 @default.
• W2029587445 hasConceptScore W2029587445C98274493 @default.
• W2029587445 hasIssue "1" @default.
• W2029587445 hasLocation W20295874451 @default.
• W2029587445 hasLocation W20295874452 @default.
• W2029587445 hasOpenAccess W2029587445 @default.
• W2029587445 hasPrimaryLocation W20295874451 @default.
• W2029587445 hasRelatedWork W178626500 @default.
• W2029587445 hasRelatedWork W1982299412 @default.
• W2029587445 hasRelatedWork W1985224328 @default.
• W2029587445 hasRelatedWork W1998765853 @default.
• W2029587445 hasRelatedWork W2019203491 @default.
• W2029587445 hasRelatedWork W2029587445 @default.
• W2029587445 hasRelatedWork W2045224469 @default.
• W2029587445 hasRelatedWork W2066829568 @default.
• W2029587445 hasRelatedWork W2410759516 @default.
• W2029587445 hasRelatedWork W2420918848 @default.
• W2029587445 hasVolume "30" @default.

• next